Fas-ligand - Iron fist or Achilles' heel?

Clinical Immunology

Volumn 103, Issue 1, 2002, Pages 1-6

  Hohlbaum, Andreas M ^a   Saff, Rebecca R ^a   Marshak Rothstein, Ann ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Chemokines; Fas ligand; Inflammation; Monocytes macrophages; Neutrophils; Proliferation; Signaling; Transplantation

Indexed keywords

FAS LIGAND;

APOPTOSIS; CELL DEATH; DISEASE ASSOCIATION; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0036246014     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5165     Document Type: Review

References (75)

1. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
2. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
3. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells
4. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity
5. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation
6. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
7. Autocrine T-cell suicide mediated by APO-1/Fas/CD95)
8. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing
9. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with down-regulation of its proapoptotic activity and loss of liver toxicity
10. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor
11. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity
12. Activation-induced cell death
13. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
14. Inhibition of death receptor signals by cellular FLIP
15. FLIP prevents apoptosis by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation
16. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells
17. Fas-ligand induced apoptosis as a mechanism of immune privilege
18. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance
19. A role for CD95 ligand in preventing graft rejection
20. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival
21. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
22. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
23. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
24. Human lung carcinomas express Fas ligand
25. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
26. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
27. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
28. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice
29. Inhibition of the alloantibody response by CD95 ligand
30. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts
31. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells
32. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells
33. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival
34. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
35. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
36. Gene transfer of Fas-ligand induces tumor regression in vivo
37. Antitumor effect of locally produced CD95 ligand
38. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand
39. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells
40. Accelerated rejection of Fas ligand-expressing heart grafts
41. Fas ligand-transfected myoblasts and islet cell transplantation
42. Opposing effects of transmembrane and soluble Fas-ligand on inflammation and tumor cell survival
43. Association of lpr gene with graft-vs-host disease-like syndrome
44. Bone marrow transplantation from mutant lpr/lpr mice. Functional abnormalities rather than alloantigenic differences appear to determine the development of a graft-vs.-host-like syndrome
45. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis
46. Fas ligand triggers pulmonary silicosis
47. Chemotactic activity of soluble Fas ligand against phagocytes
48. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes
49. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants
50. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity
51. CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity
52. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells
53. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice
54. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction. A new role for fas ligand in inflammatory responses
55. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen
56. Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis
57. CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: A key role in brain inflammation?
58. Differential regulation and function of Fas expression on glial cells
59. Induction of the IL-10 gene via the fas receptor in monocytes - An anti-inflammatory mechanism in the absence of apoptosis
60. Fas transduces activation signals in normal human T lymphocytes
61. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways
62. Expansion and elimination of B cells in vivo: Dual roles for CD40L- and Fas (CD95)-ligands modulated by the B cell antigen receptor
63. Fas antigen signals proliferation of normal human diploid fibroblasts and its mechanism is different from tumor necrosis factor receptor
64. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin
65. Fas engagement accelerates liver regeneration after partial hepatectomy
66. Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs
67. Activation of the NF-kappaB pathway by caspase 8 and its homologs
68. Activation of NF-kappaB by FADD, Casper, and caspase-8
69. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis
70. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal
71. Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD
72. RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death
73. Daxx, a novel Fas-binding protein that activates JNK and apoptosis
74. The TNF-receptor-associated factor family: Scaffold molecules for cytokine receptors, kinases and their regulators
75. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors